We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+11.76%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.08B
AUM Growth
+$20.7M
Cap. Flow
-$60.6M
Cap. Flow %
-5.62%
Top 10 Hldgs %
20.95%
Holding
208
New
36
Increased
50
Reduced
44
Closed
33

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$22.8M
2
LEGN icon
Legend Biotech
LEGN
+$18.8M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$16.1M
4
SWTX
SpringWorks Therapeutics
SWTX
+$16M
5
UTHR icon
United Therapeutics
UTHR
+$15.2M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$20M
2
HQY icon
HealthEquity
HQY
+$18.6M
3
ESI icon
Element Solutions
ESI
+$17.4M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$14.2M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 44.2%
2 Technology 15.96%
3 Industrials 9.72%
4 Energy 6.59%
5 Consumer Staples 5.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$28.9M 2.68%
489,235
-42,058
-8% -$1.92M
SWAV
2
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$26.6M 2.47%
95,776
-4,727
-5% -$1.2M
EXE
3
Expand Energy Corp
EXE
$21.9B
$26M 2.41%
276,141
-25,448
-8% -$2.39M
WSC icon
4
WillScot Mobile Mini Holdings
WSC
$4.66B
$23.4M 2.17%
580,603
-28,511
-5% -$1.11M
ARGX icon
5
argenx
ARGX
$52B
$23.4M 2.17%
66,249
-13,776
-17% -$5.1M
CYTK icon
6
Cytokinetics
CYTK
$10.4B
$22.9M 2.12%
+472,839
New +$22.8M
ESTA icon
7
Establishment Labs
ESTA
$2.73B
$20.1M 1.86%
367,630
+6,615
+2% +$395K
NARI
8
DELISTED
Inari Medical, Inc. Common Stock
NARI
$18.3M 1.7%
252,376
+6,084
+2% +$453K
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$18.2M 1.69%
390,678
-43,281
-10% -$2.26M
VRTX icon
10
Vertex Pharmaceuticals
VRTX
$119B
$18.2M 1.69%
62,779
+710
+1% +$204K
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$17.4M 1.61%
77,254
+21,493
+39% +$4.35M
BILL icon
12
BILL Holdings
BILL
$4.7B
$17M 1.57%
128,236
+16,234
+14% +$2.33M
RGEN icon
13
Repligen
RGEN
$8.3B
$16.4M 1.52%
87,722
-24,057
-22% -$5.07M
LEGN icon
14
Legend Biotech
LEGN
$3.68B
$16.3M 1.51%
+399,486
New +$18.8M
BJ icon
15
BJs Wholesale Club
BJ
$12.4B
$16.3M 1.51%
223,287
+20,962
+10% +$1.5M
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
$15.9M 1.47%
+557,175
New +$16M
KRYS icon
17
Krystal Biotech
KRYS
$9.21B
$15.5M 1.43%
222,026
-5,851
-3% -$423K
DAWN
18
DELISTED
Day One Biopharmaceuticals
DAWN
$15.2M 1.41%
+757,407
New +$16.1M
TFII icon
19
TFI International
TFII
$11.1B
$15.1M 1.4%
166,985
+30,000
+22% +$2.91M
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$15M 1.39%
243,121
+28,844
+13% +$2.02M
UTHR icon
21
United Therapeutics
UTHR
$25.7B
$14.3M 1.32%
+68,190
New +$15.2M
XOM icon
22
ExxonMobil
XOM
$643B
$14.2M 1.32%
163,000
-30,000
-16% -$2.74M
ASND icon
23
Ascendis Pharma A/S
ASND
$16B
$14.2M 1.32%
137,554
+30,623
+29% +$2.9M
MPWR icon
24
Monolithic Power Systems
MPWR
$66B
$14.1M 1.31%
38,835
-7,009
-15% -$3.12M
CUTR
25
DELISTED
Cutera, Inc.
CUTR
$13.4M 1.25%
294,602
+7,014
+2% +$320K
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Nicholas Investment Partners held 208 positions worth $1.08B, up 2% from $1.06B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Nicholas Investment Partners withdrew a net $60.6M in Q3 2022, closing 33 positions and reducing 44 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $20M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 41% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Cytokinetics worth $22.9M.

  • Nicholas Investment Partners's largest Q3 2022 buy was Cytokinetics: 472,839 shares worth $22.9M.
  • Nicholas Investment Partners added most to Callaway Golf Company in Q3 2022, an estimated $9.5M increase.
  • Nicholas Investment Partners's biggest Q3 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $14.2M.
  • Nicholas Investment Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022, selling an estimated $20M.
  • Nicholas Investment Partners's ten largest holdings make up 21% of its $1.08B portfolio in Q3 2022.
  • Nicholas Investment Partners opened 36 new positions and closed 33 in Q3 2022.
  • Nicholas Investment Partners's portfolio value rose 2% quarter-over-quarter to $1.08B.

Based on Nicholas Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.